Special Issue

Towards Precision Medicine for Cerebrovascular Diseases

Message from the Guest Editor

Cerebrovascular diseases have seen an enormous advance of new treatment options, including endovascular management of large vessel occlusions for stroke, aneurysm treatment options, radiosurgery for arteriovenous malformations, and management of cavernous malformation. This Special Issue aims to invite studies that address an individualized approach to the prevention and management of cerebrovascular diseases. It will look closely at the latest endovascular management options for stroke and aneurysms and how different treatment tools should be custom tailored to individual patients using the latest technology. Beyond endovascular and surgical treatment options, the availability of novel platelet inhibitors and oral anticoadulants makes the application of precision medicine concepts relevant for individualized treatment of patients suffering from strokes, atherosclerosis, and venous thrombosis. Finally, the prevention of cerebrovascular disease has undergone enormous progress, and understanding a patient's individual risk factors will also be an important focus of this Special Issue.

Guest Editor

Dr. Phil Taussky

Department of Neurosurgery, University of Utah Health, Salt Lake City, UT 84132, USA

Deadline for manuscript submissions

closed (5 March 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/93219

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

